LLY

1,053.12

-0.96%↓

JNJ

246.65

+0.28%↑

ABBV

228.25

-0.23%↓

NVS

167.44

+1.26%↑

MRK

124.14

+0.56%↑

LLY

1,053.12

-0.96%↓

JNJ

246.65

+0.28%↑

ABBV

228.25

-0.23%↓

NVS

167.44

+1.26%↑

MRK

124.14

+0.56%↑

LLY

1,053.12

-0.96%↓

JNJ

246.65

+0.28%↑

ABBV

228.25

-0.23%↓

NVS

167.44

+1.26%↑

MRK

124.14

+0.56%↑

LLY

1,053.12

-0.96%↓

JNJ

246.65

+0.28%↑

ABBV

228.25

-0.23%↓

NVS

167.44

+1.26%↑

MRK

124.14

+0.56%↑

LLY

1,053.12

-0.96%↓

JNJ

246.65

+0.28%↑

ABBV

228.25

-0.23%↓

NVS

167.44

+1.26%↑

MRK

124.14

+0.56%↑

Search

AngioDynamics Inc

Открыт

СекторЗдравоохранение

11.37 3.36

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

10.96

Макс.

11.58

Ключевые показатели

By Trading Economics

Доход

4.6M

-6.4M

Продажи

3.7M

79M

Рентабельность продаж

-7.994

Сотрудники

675

EBITDA

4.4M

-436K

Рекомендации

By TipRanks

Рекомендации

Активная покупка

Прогноз на 12 месяцев

+72.28% upside

Дивиденды

By Dow Jones

Следующий отчет о доходах

1 апр. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

-93M

452M

Предыдущая цена открытия

8.01

Предыдущая цена закрытия

11.37

Новостные настроения

By Acuity

50%

50%

149 / 351 Рейтинг в Healthcare

Техническая оценка

By Trading Central

Уверенность

Bearish Evidence

AngioDynamics Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

23 февр. 2026 г., 22:53 UTC

Приобретения, слияния, поглощения

Keurig Dr Pepper Raises Additional $1.5 Billion in Deal to Split Company

23 февр. 2026 г., 22:36 UTC

Отчет

Kratos Defense & Security Solutions 4Q Profit Rises; Sees Federal Shutdown Denting 1Q -- Update

23 февр. 2026 г., 22:32 UTC

Отчет

Woodside Energy Fiscal Year Net Profit Falls 24%

23 февр. 2026 г., 23:58 UTC

Обсуждения рынка
Отчет

Plenty of Questions for Woodside Despite Well-Guided Result -- Market Talk

23 февр. 2026 г., 23:58 UTC

Обсуждения рынка
Отчет

Global Energy Roundup: Market Talk

23 февр. 2026 г., 23:47 UTC

Обсуждения рынка

Scentre's Share Price Slips as Earnings Guidance Underwhelms -- Market Talk

23 февр. 2026 г., 23:43 UTC

Обсуждения рынка

Gold Edges Higher Amid Ongoing Tariff Risks -- Market Talk

23 февр. 2026 г., 23:41 UTC

Приобретения, слияния, поглощения

Crescent Capital Partners Owns 53% of ClearView Wealth

23 февр. 2026 г., 23:40 UTC

Приобретения, слияния, поглощения

ClearView Wealth Says Crescent Capital Partners Intends to Support Deal

23 февр. 2026 г., 23:40 UTC

Приобретения, слияния, поглощения

ClearView Wealth Says Directors Unanimously Recommend Shareholders Vote in Favor of Deal

23 февр. 2026 г., 23:40 UTC

Обсуждения рынка

Nikkei May Rise as Investors Assess Tariff Developments -- Market Talk

23 февр. 2026 г., 23:40 UTC

Приобретения, слияния, поглощения

ClearView Wealth Says Zurich Insurance Offering A$0.65/Share in Cash

23 февр. 2026 г., 23:39 UTC

Приобретения, слияния, поглощения

ClearView Wealth Agrees to Takeover by Zurich Insurance Group Unit

23 февр. 2026 г., 23:31 UTC

Отчет

United Overseas Bank 2025 Total Dividend S$1.56/Shr >U11.SG

23 февр. 2026 г., 23:31 UTC

Отчет

United Overseas Bank Proposes Final Dividend of S$0.71/Shr Vs. S$0.92/Shr >U11.SG

23 февр. 2026 г., 23:28 UTC

Отчет

United Overseas Bank 4Q Net Interest Income S$2.35B Vs. S$2.45B >U11.SG

23 февр. 2026 г., 23:28 UTC

Отчет

United Overseas Bank 4Q Oper Pft S$1.76B Vs. Pft S$1.88B >U11.SG

23 февр. 2026 г., 23:28 UTC

Отчет

United Overseas Bank 4Q Total Income S$3.29B Vs. S$3.46B >U11.SG

23 февр. 2026 г., 23:27 UTC

Отчет

United Overseas Bank 4Q Net S$1.41B Vs. Net S$1.52B >U11.SG

23 февр. 2026 г., 23:24 UTC

Обсуждения рынка

Major Miners On Whole Delivered Positive Earnings Season -- Market Talk

23 февр. 2026 г., 22:38 UTC

Приобретения, слияния, поглощения

Keurig Dr Pepper Raises Additional $1.5B in Deal to Split Company

23 февр. 2026 г., 22:31 UTC

Отчет

Hims & Hers Stock Falls. Why Earnings Are Underwhelming Investors. -- Barrons.com

23 февр. 2026 г., 22:24 UTC

Отчет

Viva Energy Energy & Infrastructure Ebitda A$93 Million

23 февр. 2026 г., 22:22 UTC

Отчет

Viva Energy FY Commercial & Industrial Ebitda A$460.5 Million

23 февр. 2026 г., 22:22 UTC

Отчет

Viva Energy FY Convenience & Mobility Ebitda A$197.4 Million

23 февр. 2026 г., 22:22 UTC

Отчет

Viva Energy FY Underlying Ebitda A$700.9 Million

23 февр. 2026 г., 22:22 UTC

Отчет

Viva Energy Final Dividend 3.94 Australian Cents/Security

23 февр. 2026 г., 22:21 UTC

Отчет

Viva Energy FY Revenue A$28.53 Billion, Down 1.1%

23 февр. 2026 г., 22:21 UTC

Отчет

Viva Energy FY Replacement-Cost Net Profit A$183.6 Million, Down 28%

23 февр. 2026 г., 22:20 UTC

Отчет

Viva Energy FY Historical-Cost Net Loss A$421.1 Million

Сравнение c конкурентами

Изменение цены

AngioDynamics Inc Прогноз

Целевая цена

By TipRanks

72.28% рост

Прогноз на 12 месяцев

Средняя 19.33 USD  72.28%

Максимум 24 USD

Минимум 16 USD

Основано на мнении 3 аналитиков Wall Street, спрогнозировавших целевые цены для AngioDynamics Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

3 ratings

3

Покупка

0

Удержание

0

Продажа

Техническая оценка

By Trading Central

9 / 9.3Поддержка и Сопротивление

Краткосрочная

Bearish Evidence

Среднесрочная

Very Strong Bearish Evidence

Долгосрочная

Bullish Evidence

Настроения

By Acuity

149 / 351Рейтинг в Здравоохранение

Новостные настроения

Neutral

Волатильность

Ниже среднего

Объем новостей (RCV)

Выше среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании AngioDynamics Inc

AngioDynamics, Inc., a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium. Its thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac venous drainage cannula and extracorporeal circuit, indicated for extracorporeal circulatory support for periods of up to six hours including off-the-shelf pump, filter, and reinfusion cannula, to facilitate venous drainage as part of an extracorporeal bypass procedure. The company also offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which includes angiographic catheters, and diagnostic and interventional guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits used during peripheral diagnostic and interventional procedures. In addition, it provides drainage catheters for multi-purpose/general, nephrostomy, and biliary drainage; micro-Access kits provides interventional physicians a smaller introducer system for minimally invasive procedures; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero MTA System includes solero microwave generator and the specially designed solero MW applicators. The company was founded in 1988 and is headquartered in Latham, New York.
help-icon Live chat